journal article·2026-06Open access

FASLG Derived from Fibroblasts in Hydroxyapatite‐Rich Microenvironment Induces Urothelial Anoikis to Trigger Randall's Plaque Exposure

Minghui Liu, Maolan Wu, Meng Gao, Yongchao Li, Miao Yuan, Zhangcheng Liao, Zhi Liu, Yizhou Wang, Yu Cui, Jinbo Chen, Cheng He, Zhiyong Chen, Feng Zeng, Hequn Chen, Zewu Zhu

Advanced Science· Volume 13· Issue 34

Abstract

ABSTRACT Calcium Oxalate (CaOx) kidney stones with high recurrence are a major clinical and economic health burden. Randall's Plaques (RP) serve as a nidus for CaOx stones, but it remains poorly understood how renal interstitial hydroxyapatite (HAP) deposition erodes through the papillary urothelium to create sites for urinary CaOx crystal adherence. Here, it is observed loss of urothelium above interstitial HAP deposition, and revealed that Fas Ligand (FASLG) derived from renal interstitial fibroblasts (RIFs) in HAP‐rich microenvironment induced anoikis of urothelium to trigger RP exposure to urine. Mechanistically, HAP interacted with membrane protein THY1 of RIFs, which increased the affinity of THY1 to SFRP1 but suppressed its affinity to NDP, leading to activation of GSK3α/β–β‐catenin pathway and thus upregulating FASLG. Moreover, the upregulated FASLG is identified as the predictor for recurrence in patients with CaOx stones following lithotripsy. Furthermore, Benarthin, a small compound binding to THY1, is found to inhibit HAP‐induced FASLG and thus attenuate the anoikis of urothelium in RP mice. It is anticipated that investigations of urothelial anoikis caused by FASLG from HAP‐induced fibroblasts will offer novel insights into RP exposure, enabling preventive strategies for CaOx stone formation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Kidney Stones and Urolithiasis Treatments · Chronic Kidney Disease and Diabetes · Bladder and Urothelial Cancer Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology Xiangya Hospital Central South University Changsha Hunan China

National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan China

Institute of Physiology University of Zurich Zurich Switzerland

Department of Urology Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College Beijing China

Department of Urology Hunan University of Medicine General Hospital Huaihua Hunan China

Department of Internal Medicine Section Endocrinology Yale University School of Medicine New Haven Connecticut USA

Funding

National Natural Science Foundation of China

References (100+)

Show source-provided references
1. 10.3390/healthcare1103042410.3390/healthcare11030424 ↗
2. 10.1111/bju.1617910.1111/bju.16179 ↗
3. 10.1681/ASN.201406063110.1681/ASN.2014060631 ↗
4. Urolithiasis–An Interdisciplinary Diagnostic, Therapeutic and Secondary Preventive Challenge
5. 10.1038/nrdp.2016.810.1038/nrdp.2016.8 ↗
6. 10.1097/00000658-193706000-0001410.1097/00000658-193706000-00014 ↗
7. 10.1007/s00240-014-0705-910.1007/s00240-014-0705-9 ↗
8. 10.1172/JCI1703810.1172/JCI17038 ↗
9. 10.1111/j.1464-410X.2009.08637.x10.1111/j.1464-410X.2009.08637.x ↗
10. 10.1089/end.2006.20.88510.1089/end.2006.20.885 ↗
11. 10.1007/s00240-020-01216-410.1007/s00240-020-01216-4 ↗
12. 10.1007/s00345-018-02616-310.1007/s00345-018-02616-3 ↗
13. 10.1016/j.juro.2016.04.08610.1016/j.juro.2016.04.086 ↗
14. 10.1021/acsnano.9b0766410.1021/acsnano.9b07664 ↗
15. 10.1097/MD.000000000000056610.1097/MD.0000000000000566 ↗
16. 10.1097/01.ju.0000147270.68481.ce10.1097/01.ju.0000147270.68481.ce ↗
17. 10.1016/j.juro.2011.10.12510.1016/j.juro.2011.10.125 ↗
18. The Role of Randall Plaques on Kidney Stone Formation
19. 10.1007/s00240-014-0703-y10.1007/s00240-014-0703-y ↗
20. 10.1038/s41581-020-00392-110.1038/s41581-020-00392-1 ↗
21. 10.1016/j.immuni.2023.12.00310.1016/j.immuni.2023.12.003 ↗
22. 10.1038/s41467-023-38975-810.1038/s41467-023-38975-8 ↗
23. 10.1002/advs.20240587510.1002/advs.202405875 ↗
24. 10.1007/s00018-021-03972-x10.1007/s00018-021-03972-x ↗
25. 10.1016/S0022-5347(17)61284-910.1016/S0022-5347(17)61284-9 ↗
26. 10.1146/annurev.genet.33.1.2910.1146/annurev.genet.33.1.29 ↗
27. 10.1038/3503772810.1038/35037728 ↗
28. 10.1152/ajprenal.00035.201810.1152/ajprenal.00035.2018 ↗
29. 10.1039/C1CS15188F10.1039/C1CS15188F ↗
30. 10.1111/j.1523-1755.2004.00867.x10.1111/j.1523-1755.2004.00867.x ↗
31. 10.1152/ajprenal.00243.201010.1152/ajprenal.00243.2010 ↗
32. 10.1016/j.juro.2011.04.10910.1016/j.juro.2011.04.109 ↗
33. 10.1152/ajprenal.00620.200710.1152/ajprenal.00620.2007 ↗
34. 10.1021/acs.langmuir.1c0229310.1021/acs.langmuir.1c02293 ↗
35. 10.1016/j.jcis.2007.11.01510.1016/j.jcis.2007.11.015 ↗
36. 10.1007/s00223-013-9698-610.1007/s00223-013-9698-6 ↗
37. 10.1096/fj.05-5460rev10.1096/fj.05-5460rev ↗
38. 10.3389/fcell.2019.0013210.3389/fcell.2019.00132 ↗
39. 10.1016/j.pharmthera.2014.11.01610.1016/j.pharmthera.2014.11.016 ↗
40. 10.1016/j.tibs.2003.12.00410.1016/j.tibs.2003.12.004 ↗
41. 10.18632/oncotarget.203710.18632/oncotarget.2037 ↗
42. 10.1158/0008-5472.CAN-13-294610.1158/0008-5472.CAN-13-2946 ↗
43. 10.1007/s12035-017-0823-910.1007/s12035-017-0823-9 ↗
44. 10.1158/0008-5472.CAN-08-085010.1158/0008-5472.CAN-08-0850 ↗
45. 10.1016/j.cell.2017.05.01610.1016/j.cell.2017.05.016 ↗
46. 10.1038/nrm265410.1038/nrm2654 ↗
47. 10.1016/j.cell.2012.05.01210.1016/j.cell.2012.05.012 ↗
48. 10.1016/S0092-8674(04)00216-810.1016/S0092-8674(04)00216-8 ↗
49. 10.2353/ajpath.2008.07013010.2353/ajpath.2008.070130 ↗
50. 10.1038/nature0319710.1038/nature03197 ↗
51. 10.3389/fcell.2022.92851010.3389/fcell.2022.928510 ↗
52. 10.21037/atm-20-652810.21037/atm-20-6528 ↗
53. 10.1007/s00240-024-01622-y10.1007/s00240-024-01622-y ↗
54. 10.1681/ASN.V117126610.1681/ASN.V1171266 ↗
55. 10.1038/ki.2010.27010.1038/ki.2010.270 ↗
56. 10.1038/sj.cdd.440172310.1038/sj.cdd.4401723 ↗
57. 10.1016/S0955-0674(00)00251-910.1016/S0955-0674(00)00251-9 ↗
58. 10.1016/j.bbamcr.2013.06.02610.1016/j.bbamcr.2013.06.026 ↗
59. 10.1016/j.urology.2013.08.04210.1016/j.urology.2013.08.042 ↗
60. 10.1038/sj.bjc.660273210.1038/sj.bjc.6602732 ↗
61. 10.1046/j.1523-1755.2001.00771.x10.1046/j.1523-1755.2001.00771.x ↗
62. Constitutive and Induced Expression of APO‐1, a New Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Superfamily, in Normal and Neoplastic Cells
63. 10.3390/ijms2024632610.3390/ijms20246326 ↗
64. 10.1093/ndt/gfv26210.1093/ndt/gfv262 ↗
65. 10.4161/org.817310.4161/org.8173 ↗
66. 10.1111/j.1469-185X.1975.tb01057.x10.1111/j.1469-185X.1975.tb01057.x ↗
67. 10.1002/dvdy.2448710.1002/dvdy.24487 ↗
68. 10.1016/B978-1-4160-4391-1.50007-210.1016/B978-1-4160-4391-1.50007-2 ↗
69. Betts J. G. · 2022
70. 10.1016/j.juro.2008.02.04110.1016/j.juro.2008.02.041 ↗
71. 10.2147/IJN.S23292610.2147/IJN.S232926 ↗
72. 10.1038/s41598-019-55428-910.1038/s41598-019-55428-9 ↗
73. 10.1161/CIRCRESAHA.108.18130510.1161/CIRCRESAHA.108.181305 ↗
74. 10.1007/s00223-015-9962-z10.1007/s00223-015-9962-z ↗
75. Oxalate and Calcium Oxalate Crystals Are Injurious to Renal Epithelial Cells: Results of in Vivo and in Vitro Studies
76. 10.1038/cddiscovery.2015.5510.1038/cddiscovery.2015.55 ↗
77. 10.1161/01.RES.0000249379.55535.2110.1161/01.RES.0000249379.55535.21 ↗
78. 10.1093/cvr/cvy01010.1093/cvr/cvy010 ↗
79. 10.1161/CIRCULATIONAHA.120.04992210.1161/CIRCULATIONAHA.120.049922 ↗
80. 10.1161/HYPERTENSIONAHA.121.1795710.1161/HYPERTENSIONAHA.121.17957 ↗
81. 10.1161/hq0901.09427910.1161/hq0901.094279 ↗
82. Tumor Necrosis Factor Induces Apoptosis (programmed cell death) in Normal Endothelial Cells in Vitro
83. 10.1152/physrev.00048.200310.1152/physrev.00048.2003 ↗
84. 10.1016/j.ejphar.2017.09.00710.1016/j.ejphar.2017.09.007 ↗
85. 10.7164/antibiotics.45.107910.7164/antibiotics.45.1079 ↗
86. 10.7164/antibiotics.45.108410.7164/antibiotics.45.1084 ↗
87. 10.7164/antibiotics.45.108810.7164/antibiotics.45.1088 ↗
88. 10.1128/mSystems.00341-2110.1128/mSystems.00341-21 ↗
89. 10.1021/np200290j10.1021/np200290j ↗
90. 10.1016/j.yexcr.2006.07.02910.1016/j.yexcr.2006.07.029 ↗
91. 10.3389/fcell.2020.59636310.3389/fcell.2020.596363 ↗
92. 10.1016/j.ijsu.2019.10.03210.1016/j.ijsu.2019.10.032 ↗
93. Residual Fragments After Percutaneous Nephrolithotomy
94. 10.1007/978-1-4939-3353-2_210.1007/978-1-4939-3353-2_2 ↗
95. 10.1016/j.xpro.2021.10082610.1016/j.xpro.2021.100826 ↗
96. 10.1177/019262331876269410.1177/0192623318762694 ↗
97. 10.1006/cbir.2001.082910.1006/cbir.2001.0829 ↗
98. 10.1038/ki.2015.5110.1038/ki.2015.51 ↗
99. 10.1016/j.ijbiomac.2020.09.08510.1016/j.ijbiomac.2020.09.085 ↗
100. 10.1186/s10020-022-00576-410.1186/s10020-022-00576-4 ↗